INS and type 2 diabetes mellitus: Individual double‐blind RCT of vildagliptin versus placebo among women with insulin‐treated GDM within the previous 9 months. The primary outcome was worsening glycemia from baseline (development of new impaired glucose tolerance, impaired fasting glucose, or T2DM).